Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

1180503

USP

Dextromethorphan

United States Pharmacopeia (USP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H25NO
Número de CAS:
125-71-3
Peso molecular:
271.40
EC Number:
204-752-2
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

dextromethorphan

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1

InChI key

MKXZASYAUGDDCJ-NJAFHUGGSA-N

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dextromethorphan USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

PHR1018

Dextromethorphan HBr, certified reference material, pharmaceutical secondary standard

1181007

Dextromethorphan hydrobromide, United States Pharmacopeia (USP) Reference Standard

D0740000

Dextromethorphan hydrobromide, European Pharmacopoeia (EP) Reference Standard

Y0000261

Dextromethorphan impurity A, European Pharmacopoeia (EP) Reference Standard

1181040

Dextromethorphan Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR2206

Dextromethorphan N-Oxide HCl, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1976

Dextromethorphan Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

hcodes

H301,H411

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Eric Guenin et al.
Clinical drug investigation, 34(9), 609-616 (2014-07-17)
Dextromethorphan hydrobromide (DM) is a widely used antitussive. This study determined, for the first time, the basic pharmacokinetic profile of DM and its active metabolite, dextrorphan (DP) in children and adolescents. Thirty-eight male and female subjects at risk for developing
Rüdiger Kaspera et al.
Biochemical pharmacology, 91(1), 109-118 (2014-06-29)
Ritonavir, an HIV protease inhibitor, is successfully used for the prevention and treatment of HIV infections. Ritonavir pharmacokinetics are complicated by inhibition, induction and pharmacogenetics of cytochrome P450 (CYP) enzymes mediating its clearance. This investigation revealed that CYP2J2, along with
Jasbir D Upadhyaya et al.
PloS one, 9(10), e110373-e110373 (2014-10-24)
Activation of bitter taste receptors (T2Rs) in human airway smooth muscle cells leads to muscle relaxation and bronchodilation. This finding led to our hypothesis that T2Rs are expressed in human pulmonary artery smooth muscle cells and might be involved in
Sang Yoon Lee et al.
Toxicology letters, 229(1), 33-40 (2014-06-10)
Although cytochrome P450 inhibition is the major drug-drug interaction (DDI) mechanism in clinical pharmacotherapy, DDI of a number of well-established drugs have not been investigated. Rifampicin, isoniazid, pyrazinamide and ethambutol combination therapy inhibits clearance of theophylline in patients with tuberculosis.
Sang Yoon Lee et al.
Xenobiotica; the fate of foreign compounds in biological systems, 45(2), 131-138 (2014-08-26)
1. The herb-drug interaction potential of Hwang-Ryun-Hae-Dok-Tang (HR) extracts mediated by cytochrome P450 (CYP) inhibition was determined using human liver microsomes. 2. HR strongly inhibited CYP1A2 and moderately inhibited CYP2C19, CYP2D6, and CYP3A4 (testosterone) but not CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP3A4
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico